1. A sustained decrease of up to 12 months in serum IgA measurements was demonstrated after administration of CTL019 transfusion in a patient with multiple myeloma (MM). 2. A sustained decrease of up to 12 months in malignant plasma cells on bone marrow biopsy was demonstrated after administration of CTL019 transfusion. Evidence Rating: 4 (Below average)
↧
